Liminatus Pharma, Inc. Class A Common Stock
LIMN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $1 | $0 | $5 | $0 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $0 | $1 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $0 | -$1 | -$5 | $0 |
| Total Curr. Assets | $1 | $0 | $0 | $0 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $2 | $4 | $15 | $276 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | -$0 | -$0 | $0 |
| Total NC Assets | $2 | $4 | $15 | $276 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $3 | $5 | $15 | $276 |
| Liabilities | – | – | – | – |
| Payables | $1 | $1 | $1 | $0 |
| Short-Term Debt | $5 | $16 | $17 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $2 | -$12 | -$13 | $1 |
| Total Curr. Liab. | $9 | $5 | $4 | $1 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $10 | $10 | $11 | $20 |
| Total NC Liab. | $10 | $10 | $11 | $20 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $19 | $15 | $14 | $22 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $2 | $4 | $15 | $276 |
| Retained Earnings | -$18 | -$15 | -$14 | -$21 |
| AOCI | -$0 | $0 | $0 | $0 |
| Other Equity | $0 | $0 | $0 | $0 |
| Total Equity | -$16 | -$11 | $1 | $255 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $3 | $5 | $15 | $276 |
| Net Debt | $4 | $16 | $11 | -$0 |